Biologics for the treatment of systemic lupus erythematosus are commercially available in China

Fabio Landazabal, senior vice president of emerging markets at GSK, said: "The majority of SLE patients are women of childbearing age aged 15-45As a drug designed and developed specifically for the treatment of SLE, Bellieumono helps reduce long-term organ damage and delay disease progressionWe hope that more SLE patients will benefit from the treatment of GSK's innovative drugs for the benefit of more Chinese patients"
GSK Senior Vice President of Emerging Markets, MrFabio Landazabal,the current situation of lupus erythematosus in China: the number of cases, early onset, organ damageSLE is an autoimmune disease that can lead to damage to kidneys, cardiovascular, respiratory, digestive system, blood system, blood vessels, eyes, and other organs, tissues, and significantly increase the risk of deathZeng Xiaofeng, director of rheumatology immunology at Beijing Concord Hospital, said: "Compared with the European and American population, the sLE in the Chinese group is earlier and more serious." Although SLE is a chronic disease, it can cause extensive organ damage at an early stage of the diseaseProfessor Zeng Xiaofeng, Director of Rheumatology immunology at Beijing Concord Hospital,, saidstudy showed that about 40% of SLE patients had organ damage in the first year, and 50% had irreversible organ damage within five years of the onset of the diseaseSLE patients have a three-fold mortality rate than their normal peers, a five-fold increase in the risk of dying from infection, and an eight-fold increase in the risk of dying from kidney disease, with infection the leading cause of death among SLE patients in ChinaIn order to effectively reduce the serious harm of SLE, the European Union against Rheumatology (EULAR) 2019 recommended SLE treatment that sLEE's goal is to alleviate disease symptoms or maintain low disease activity, reduce disease recurrence, and reduce the toxic side effects of the drug, thereby reducing the cumulative damage to tissue organs and improving the quality of life of patients, however, there are still some challenges in the process of achieving the standards of the treatment drugs in our countrybio-targeted preparations: to give patients more choice
Zeng Xiaofeng introduced: "In the past, the treatment of systemic lupus drugs are three categories: hormones, immunosuppressants and antimalarial drugs, and these three types of drugs, are the treatment of the disease." Under conventional treatment, SLE is faced with poor disease control and drug toxicity caused by the double damage, there are still nearly 60% of patients with persistent disease activity or recurrence, the traditional SLE treatment drugs have a certain drug toxicity, long-term high dose use will induce and aggravate infection, as well as liver function damage, bone marrow inhibition, eye lesions and other adverse reactions Although the ten-year survival rate of SLE patients has been improved, how to better control disease activity, reduce disease recurrence, delay organ damage, reduce adverse drug reactions and improve the quality of life is an urgent problem to be solved by SLE treatment Zeng Xiaofeng introduced: "Baileyu single anti-target action SLE pathogenic key - B cell pathway, inhibit b cell excessive proliferation differentiation, induce auto-reactive B-cell apoptosis, thereby reducing the self-antibody in the serum, to achieve the purpose of treating systemic lupus." Clinical studies of Bellieu monosantion in Chinese patients have also shown good results The study data confirmed that in Asia, especially in adult sLE patients in China, Bellevue monoantigen combined routine treatment for 52 weeks, the combined response rate of systemic lupus response index as high as 57.8%, the risk of severe recurrence decreased by 50%, while significantly reducing the cumulative hormone dose and the disease remained stable, the overall incidence of adverse reactions was similar to placebo We look forward to further controlling diseases with poor control and reducing the amount of hormones in patients, thereby reducing long-term organ damage through the treatment of Bellieu's monoresist 2019 European Association against Rheumatology (EULAR) recommendations for systemic lupus erythematosus (SLE) treatment indicate that patients who are poorly responded to conventional treatment (antimalarial drug-glucocorticoid combination/non-joint immunosuppressant) (due to residual disease activity hormone incapacity and/or recurrence) should consider adding Bellevue monoantigen (1a/A) it is learned that at the upcoming 2nd China International Import Expo, GlaxoSmithKline will bring a number of innovative drugs out of the exhibition, including Bellevue, GlaxoSmithKline will be in the Expo as an opportunity to share the company's global innovation results with China, practice the "based on China, hand in hand with China, serve China" concept "GSK is committed to improving the treatment of SLE disease," Fabio Landazabal stressed SLE patients are brave and resilient in their fight against the disease As a responsible pharmaceutical company, we understand the situation of these patients and will accelerate our pace and conduct more clinical trials to help more patients benefit from the treatment of Beliho monoantigen "